X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5144) 5144
animals (3569) 3569
tetrazoles - pharmacology (3402) 3402
male (3065) 3065
rats (2328) 2328
humans (2275) 2275
tetrazoles - therapeutic use (1280) 1280
female (1217) 1217
pharmacology & pharmacy (1197) 1197
angiotensin receptor antagonists (1161) 1161
imidazoles - pharmacology (1132) 1132
biphenyl compounds - pharmacology (1015) 1015
blood pressure - drug effects (908) 908
losartan (906) 906
rats, sprague-dawley (828) 828
benzimidazoles - pharmacology (818) 818
hypertension (784) 784
peripheral vascular disease (783) 783
valsartan (757) 757
angiotensin ii type 1 receptor blockers - pharmacology (751) 751
middle aged (712) 712
valine - analogs & derivatives (679) 679
mice (678) 678
antihypertensive agents - pharmacology (667) 667
hypertension - drug therapy (652) 652
angiotensin (647) 647
tetrazoles - administration & dosage (640) 640
angiotensin ii (626) 626
angiotensin ii - pharmacology (572) 572
dose-response relationship, drug (571) 571
angiotensin ii - metabolism (531) 531
adult (525) 525
rats, wistar (521) 521
aged (503) 503
cardiac & cardiovascular systems (500) 500
pyridines - pharmacology (495) 495
expression (482) 482
disease models, animal (478) 478
cells, cultured (473) 473
antihypertensive agents - therapeutic use (456) 456
angiotensin ii type 1 receptor blockers - therapeutic use (450) 450
valine - pharmacology (405) 405
blood-pressure (387) 387
time factors (387) 387
tetrazoles - pharmacokinetics (382) 382
receptors, angiotensin - metabolism (381) 381
in vitro techniques (380) 380
angiotensin ii - antagonists & inhibitors (371) 371
oxidative stress (371) 371
tetrazoles - metabolism (352) 352
hypertension - physiopathology (349) 349
receptor, angiotensin, type 1 (346) 346
biphenyl compounds - therapeutic use (340) 340
angiotensin-converting enzyme inhibitors - pharmacology (337) 337
treatment outcome (336) 336
benzimidazoles - therapeutic use (332) 332
biochemistry & molecular biology (330) 330
endocrinology & metabolism (329) 329
physiology (327) 327
tetrazoles - chemistry (325) 325
renin-angiotensin system (316) 316
angiotensin-ii (307) 307
renin-angiotensin system - drug effects (306) 306
abridged index medicus (305) 305
blood pressure (302) 302
cilostazol (299) 299
drug therapy, combination (292) 292
tetrazoles (287) 287
rna, messenger - metabolism (286) 286
candesartan (282) 282
receptor (281) 281
receptor, angiotensin, type 1 - metabolism (277) 277
rats, inbred shr (276) 276
inhibition (275) 275
neurosciences (269) 269
valine - therapeutic use (266) 266
activation (265) 265
hypertension - metabolism (259) 259
kidney - metabolism (257) 257
rat (257) 257
tetrazoles - adverse effects (254) 254
analysis (251) 251
inflammation (248) 248
research (248) 248
rabbits (246) 246
myocardium - metabolism (245) 245
urology & nephrology (245) 245
system (238) 238
kidney - drug effects (237) 237
imidazoles - therapeutic use (236) 236
receptor, angiotensin, type 2 (234) 234
irbesartan (230) 230
mice, inbred c57bl (230) 230
chemistry, medicinal (226) 226
cells (225) 225
antihypertensive agents - administration & dosage (223) 223
double-blind method (218) 218
structure-activity relationship (213) 213
pharmacokinetics (208) 208
receptors (207) 207
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5213) 5213
Chinese (74) 74
Japanese (36) 36
Russian (28) 28
German (12) 12
French (4) 4
Hungarian (4) 4
Italian (4) 4
Ukrainian (3) 3
Dutch (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drug Metabolism and Disposition, ISSN 0090-9556, 09/2012, Volume 40, Issue 9, pp. 1744 - 1756
Interindividual variability in activity of uptake transporters is evident in vivo, yet limited data exist in vitro, confounding in vitro-in vivo extrapolation.... 
DRUG TRANSPORTERS | IN-VITRO CLEARANCE | CRYOPRESERVED HUMAN HEPATOCYTES | HMG-COA REDUCTASE | PHARMACOLOGY & PHARMACY | ANION TRANSPORTING POLYPEPTIDES | HEPATIC-UPTAKE | HEALTHY-VOLUNTEERS | METABOLIC ENZYMES | RECEPTOR ANTAGONIST | PREDICTION | Antihypertensive Agents - pharmacology | Tetrazoles - pharmacology | Species Specificity | Valsartan | Hypoglycemic Agents - metabolism | Benzoates - metabolism | Humans | Antihypertensive Agents - metabolism | Hepatocytes - metabolism | Angiotensin II Type 1 Receptor Blockers - pharmacology | Angiotensin II Type 1 Receptor Blockers - metabolism | Organic Anion Transporters - metabolism | Pyrimidines - metabolism | Quinolines - pharmacology | Tetrazoles - metabolism | Carbamates - metabolism | Dose-Response Relationship, Drug | Fluorobenzenes - pharmacology | Drug Interactions | Hydroxymethylglutaryl-CoA Reductase Inhibitors - metabolism | Biological Transport | Piperidines - pharmacology | Hepatocytes - drug effects | Carbamates - pharmacology | Pravastatin - pharmacology | Fluorobenzenes - metabolism | Piperidines - metabolism | Pravastatin - metabolism | Valine - analogs & derivatives | Rats | Rosuvastatin Calcium | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Hypoglycemic Agents - pharmacology | Quinolines - metabolism | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Valine - metabolism | Models, Biological | Benzimidazoles - metabolism | Sulfonamides - metabolism | Benzoates - pharmacology | Benzimidazoles - pharmacology | Kinetics | Valine - pharmacology | Organic Anion Transporters - drug effects | Index Medicus
Journal Article
Kidney International, ISSN 0085-2538, 02/2009, Volume 75, Issue 3, pp. 285 - 294
Urinary neutrophil gelatinase-associated lipocalin (Ngal or lipocalin 2) is a very early and sensitive biomarker of kidney injury. Here we determined the... 
albuminuria | acute renal failure | obstructive nephropathy | diabetic nephropathy | nephrotic syndrome | Diabetic nephropathy | Obstructive nephropathy | Nephrotic syndrome | Albuminuria | Acute renal failure | NGAL | ACUTE KIDNEY INJURY | MOUSE | DIABETIC-NEPHROPATHY | IRON | TISSUE GROWTH-FACTOR | CARDIAC-SURGERY | INSULIN-RESISTANCE | UROLOGY & NEPHROLOGY | ALBUMIN | RENAL INJURY | Acute-Phase Proteins - urine | Biomarkers - urine | Nephrotic Syndrome - urine | Nephritis, Interstitial - urine | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Proto-Oncogene Proteins - urine | Nephrotic Syndrome - metabolism | Lipocalins - urine | Loop of Henle - metabolism | Ureteral Obstruction - metabolism | RNA, Messenger - metabolism | Nephritis, Interstitial - metabolism | Time Factors | Sensitivity and Specificity | Kidney Glomerulus - metabolism | Diabetes Mellitus, Experimental - metabolism | Benzimidazoles - therapeutic use | Disease Models, Animal | Diabetic Nephropathies - urine | Lipocalins - metabolism | Proto-Oncogene Proteins - metabolism | Kidney Tubules, Proximal - cytology | Acute-Phase Proteins - metabolism | Albumins - metabolism | Diabetic Nephropathies - metabolism | Mice, Inbred C57BL | Mice, Transgenic | Animals | Lipocalin-2 | Kidney Tubules, Proximal - metabolism | Tetrazoles - therapeutic use | Mice | Acute Kidney Injury - metabolism | Nephrons - metabolism | Index Medicus
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 12/2007, Volume 35, Issue 12, pp. 2166 - 2176
Olmesartan, a novel angiotensin II AT1-receptor antagonist, is excreted into both bile and urine, with minimal metabolism. Because olmesartan is a hydrophilic... 
PHARMACOKINETICS | INVOLVEMENT | PHARMACOLOGY & PHARMACY | RESISTANCE-ASSOCIATED PROTEIN-4 | ORGANIC ANION TRANSPORTERS | EXCRETION | IDENTIFICATION | MEDOXOMIL | EXPRESSION | OATP1B1 | BLOCKER | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Membrane Transport Proteins - drug effects | Hepatocytes - metabolism | Imidazoles - pharmacokinetics | Neoplasm Proteins - metabolism | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Sincalide - metabolism | Angiotensin II Type 1 Receptor Blockers - metabolism | Organic Anion Transporters - metabolism | Prodrugs - metabolism | Tetrazoles - metabolism | Dose-Response Relationship, Drug | Kidney - metabolism | Protein Isoforms - metabolism | Transfection | Liver - drug effects | Membrane Transport Proteins - genetics | Organic Anion Transporters, Sodium-Independent - metabolism | Adenosine Triphosphate - metabolism | ATP-Binding Cassette Transporters - metabolism | Female | Membrane Transport Proteins - metabolism | Hepatocytes - drug effects | Solute Carrier Organic Anion Transporter Family Member 1B3 | Imidazoles - metabolism | Olmesartan Medoxomil | Cell Line | Liver - metabolism | Probenecid - pharmacology | Penicillin G - pharmacology | Mice, Knockout | p-Aminohippuric Acid - pharmacology | Animals | Estrone - analogs & derivatives | Multidrug Resistance-Associated Proteins - deficiency | Prodrugs - pharmacokinetics | Estrone - metabolism | Dogs | Protein Binding | ATP Binding Cassette Transporter, Sub-Family B | Mice | Kinetics | In Vitro Techniques | Solute Carrier Organic Anion Transporter Family Member 1b1 | Multidrug Resistance-Associated Proteins - metabolism | Tetrazoles - pharmacokinetics | Index Medicus
Journal Article
American Journal of Physiology - Heart and Circulatory Physiology, ISSN 0363-6135, 05/2013, Volume 305, Issue 4, pp. H599 - H607
Activation of angiotensin receptor type 1 (AT1) contributes to NADPH oxidase (Nox)-derived oxidative stress during metabolic syndrome. However, the specific... 
Metabolic syndrome | Nrf2 | NADPH oxidase | CARDIAC & CARDIOVASCULAR SYSTEMS | PHYSIOLOGY | ENDOTHELIAL DYSFUNCTION | HEART-FAILURE | TYPE-1 RECEPTOR | INDUCED SUPEROXIDE-PRODUCTION | NADPH OXIDASE NOX4 | DIABETIC CARDIOVASCULAR DISORDERS | metabolic syndrome | CROSS-TALK | IN-VIVO | PERIPHERAL VASCULAR DISEASE | HYPERTENSION | Mitochondria, Heart - metabolism | Tetrazoles - pharmacology | Membrane Glycoproteins - metabolism | NADPH Oxidases - metabolism | Male | Aldehydes - metabolism | RNA, Messenger - metabolism | Angiotensin II Type 1 Receptor Blockers - pharmacology | Obesity - genetics | Tyrosine - analogs & derivatives | Time Factors | Myocardium - metabolism | NADPH Oxidases - genetics | Citrate (si)-Synthase - metabolism | Receptor, Angiotensin, Type 1 - drug effects | Superoxide Dismutase - metabolism | Disease Models, Animal | Glutathione Peroxidase - metabolism | Oxidation-Reduction | Insulin Resistance | Rats | Obesity - physiopathology | Imidazoles - pharmacology | NADPH Oxidase 4 | NADPH Oxidase 2 | Membrane Glycoproteins - genetics | Obesity - metabolism | Catalase - metabolism | Gene Expression Regulation, Enzymologic | Rats, Inbred OLETF | Tyrosine - metabolism | Animals | Signal Transduction - drug effects | NF-E2-Related Factor 2 - metabolism | Receptor, Angiotensin, Type 1 - metabolism | Succinate Dehydrogenase - metabolism | Oxidative Stress - drug effects | Physiological aspects | Oxidative stress | Insulin resistance | Research | Insulin | Angiotensin | Proteins | Medical treatment | Lipids | Oxidation | Index Medicus | Integrative Cardiovascular Physiology and Pathophysiology
Journal Article
Journal Article
Journal Article
Molecular Biology of the Cell, ISSN 1059-1524, 03/2010, Volume 21, Issue 6, pp. 1097 - 1110
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 2011, Volume 44, Issue 5, pp. 627 - 634
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 05/2009, Volume 119, Issue 5, pp. 1312 - 1321
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2014, Volume 9, Issue 5, pp. e95313 - e95313
Cilostazol, a phosphodiesterase-III inhibitor, reportedly exhibits positive effects against ischemia/reperfusion (I/R)-induced injury in several models.... 
ISCHEMIA/REPERFUSION INJURY | DELAYED GRAFT FUNCTION | MULTIDISCIPLINARY SCIENCES | FOCAL CEREBRAL-ISCHEMIA | KIDNEY INJURY MOLECULE-1 | ACUTE-RENAL-FAILURE | SMOOTH-MUSCLE-CELLS | VASCULAR ENDOTHELIAL-CELLS | DIABETIC-RATS | KAPPA-B | III PHOSPHODIESTERASE INHIBITOR | Kidney - blood supply | Tetrazoles - pharmacology | Rats, Wistar | Cystatin C - blood | Phosphodiesterase 3 Inhibitors - pharmacology | Blood Urea Nitrogen | Caspase 1 - metabolism | Male | PPAR gamma - metabolism | Dose-Response Relationship, Drug | Kidney - metabolism | Protective Agents - pharmacology | Thiazolidinediones - pharmacology | Reperfusion Injury - metabolism | Lipocalins - metabolism | Proto-Oncogene Proteins - metabolism | Kidney - drug effects | Acute-Phase Proteins - metabolism | Random Allocation | Acute Kidney Injury - physiopathology | Cell Adhesion Molecules - metabolism | Acute Kidney Injury - prevention & control | Hypoglycemic Agents - pharmacology | Intercellular Adhesion Molecule-1 - metabolism | Animals | Reperfusion Injury - prevention & control | Reperfusion Injury - physiopathology | Creatinine - blood | Acute Kidney Injury - metabolism | Vascular Cell Adhesion Molecule-1 - metabolism | Interleukin-18 - metabolism | Nitric Oxide Synthase Type II - metabolism | Peroxidase - metabolism | Drugs | Cystatin | Oxidative stress | Vascular cell adhesion molecule 1 | Transplants & implants | Transcription | Syngeneic grafts | Dosage | Cell adhesion & migration | Caspase-1 | Elevation | Toxicology | Reperfusion | Ischemia | Rodents | Cystatin C | Tumor necrosis factor-TNF | Peroxidase | Bioindicators | Pretreatment | Injuries | Glutathione | Phosphodiesterase | Creatinine | Kidneys | Intercellular adhesion molecule 1 | Pioglitazone | Lipocalin | Neutrophils | Rats | Caspase | Pharmacology | Gelatinase | Nitric-oxide synthase | Malondialdehyde | Interleukin 18 | Endothelium | Serum levels | Urea | Nitric oxide | Biomarkers | Peroxisome proliferator-activated receptors | Diabetes | Laboratory animals | Apoptosis | Index Medicus
Journal Article
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 08/2011, Volume 31, Issue 8, pp. 1898 - 1907
OBJECTIVE—Circulating microparticles are increased in cardiovascular disease and may themselves promote oxidative stress and inflammation. Molecular mechanisms... 
endothelium | microparticles | signal transduction | angiotensin II | reactive oxygen species | NADPH OXIDASE | OXIDATIVE STRESS | SUPEROXIDE-PRODUCTION | HYPERTENSIVE PATIENTS | IN-VITRO | NAD(P)H OXIDASE | PLATELET-DERIVED MICROPARTICLES | PERIPHERAL VASCULAR DISEASE | SMOOTH-MUSCLE-CELLS | CIRCULATING MICROPARTICLES | HEMATOLOGY | E-DEFICIENT MICE | Reactive Oxygen Species - metabolism | Tetrazoles - pharmacology | Apolipoproteins E - deficiency | Membrane Microdomains - metabolism | NADPH Oxidases - metabolism | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - analogs & derivatives | Male | Angiotensin II Type 1 Receptor Blockers - pharmacology | Endothelial Cells - ultrastructure | Biphenyl Compounds - pharmacology | Cell-Derived Microparticles - drug effects | rho-Associated Kinases - metabolism | Platelet Endothelial Cell Adhesion Molecule-1 - metabolism | Acetophenones - pharmacology | Blood Pressure - drug effects | Blood Pressure - physiology | Cell-Derived Microparticles - metabolism | Cell-Derived Microparticles - ultrastructure | Microscopy, Electron, Transmission | Angiotensin II - pharmacology | Angiotensin II - metabolism | Signal Transduction | Endothelial Cells - metabolism | Hypertrophy, Left Ventricular - etiology | Mice, Inbred C57BL | Cells, Cultured | Mice, Knockout | Animals | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacology | Apolipoproteins E - genetics | Mice | Protein Kinase Inhibitors - pharmacology | Adaptor Proteins, Signal Transducing - metabolism | Vascular Cell Adhesion Molecule-1 - metabolism | Endothelial Cells - drug effects | Index Medicus
Journal Article
American Journal of Physiology - Cell Physiology, ISSN 0363-6143, 03/2015, Volume 308, Issue 6, pp. C463 - C472
Activation of the purinergic P2X7 receptor (P2X7R) has been associated with the development of experimental nephritis and diabetic and hypertensive... 
Purinergic receptors | Acute kidney injury | Apoptosis | Renal tubular cells | purinergic receptors | RENAL EPITHELIAL-CELLS | PHYSIOLOGY | ATP RECEPTOR | apoptosis | DEATH | REGULATED KINASE ACTIVATION | SENSITIVE P2X RECEPTOR | CELL BIOLOGY | PATHWAY | INFLAMMATION | acute kidney injury | HYDROGEN-PEROXIDE | renal tubular cells | EXPRESSION | Urological Agents - pharmacology | Phosphorylation | Receptors, Purinergic P2X7 - drug effects | Tetrazoles - pharmacology | Kidney - pathology | Purinergic P2X Receptor Antagonists - pharmacology | Receptors, Purinergic P2X7 - genetics | Kidney - metabolism | Transfection | RNA Interference | Time Factors | Inflammation Mediators - metabolism | Chemokine CCL2 - metabolism | Chemokine CCL5 - metabolism | Reperfusion Injury - metabolism | Kidney - physiopathology | Cytoprotection | Disease Models, Animal | Lipocalins - metabolism | Kidney - drug effects | Reperfusion Injury - pathology | Acute Kidney Injury - pathology | Acute-Phase Proteins - metabolism | Cells, Cultured | Oncogene Proteins - metabolism | Acute Kidney Injury - physiopathology | Acute Kidney Injury - prevention & control | Animals | Reperfusion Injury - prevention & control | Mitogen-Activated Protein Kinase 3 - metabolism | Signal Transduction - drug effects | Lipocalin-2 | Reperfusion Injury - physiopathology | Receptors, Purinergic P2X7 - metabolism | Pyridines - pharmacology | Acute Kidney Injury - metabolism | Mitogen-Activated Protein Kinase 1 - metabolism | Physiological aspects | Cell research | Research | Ischemia | Acute renal failure | Rodents | Protein expression | Kidney diseases | Kinases | Adenosine triphosphatase | Index Medicus
Journal Article
JOURNAL OF BIOLOGICAL CHEMISTRY, ISSN 0021-9258, 10/2017, Volume 292, Issue 40, pp. 16626 - 16637
Salivary gland inflammation is a hallmark of Sjogren's syndrome (SS), a common autoimmune disease characterized by lymphocytic infiltration of the salivary... 
EXTRACELLULAR ATP | ACTIVATION | SUBMANDIBULAR-GLAND | P2X RECEPTOR | IMMUNE-RESPONSES | BIOCHEMISTRY & MOLECULAR BIOLOGY | SJOGRENS-SYNDROME | NLRP3 INFLAMMASOME | UP-REGULATION | LUNG INFLAMMATION | NALP3 INFLAMMASOME | Potassium - metabolism | Epithelial Cells - metabolism | Tetrazoles - pharmacology | Purinergic P2X Receptor Antagonists - pharmacology | Interferon-gamma - metabolism | Sjogren's Syndrome - metabolism | Sodium - metabolism | Receptors, Purinergic P2X7 - genetics | CD28 Antigens - metabolism | NLR Family, Pyrin Domain-Containing 3 Protein - genetics | CD28 Antigens - genetics | Interleukin-1beta - metabolism | Ion Transport - drug effects | Interferon-gamma - genetics | Sjogren's Syndrome - genetics | Disease Models, Animal | Sjogren's Syndrome - pathology | Inflammasomes | NLR Family, Pyrin Domain-Containing 3 Protein - metabolism | Submandibular Gland - metabolism | Epithelial Cells - pathology | Mice, Knockout | Submandibular Gland - pathology | Animals | Receptors, Purinergic P2X7 - metabolism | Mice | Pyridines - pharmacology | Interleukin-18 - genetics | Interleukin-18 - metabolism | Ion Transport - genetics | Index Medicus | salivary gland | Molecular Bases of Disease | purinergic receptor | P2X7 | inflammation | Sjögren's syndrome | inflammasome | IL-1β | ATP | autoimmune disease | P2X7 receptor
Journal Article